CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results

Yeon Hee Park, Tae Yong Kim, Young-Hyuck Im, Keun-Seok Lee, In Hae Park, Joohyuk Sohn, Soo-Hyeon Lee, Seock-Ah Im, Jee Hyun Kim, Se Hyun Kim, Soo Jung Lee, Su-Jin Koh, Ki Hyeong Lee, Yoon Ji Choi, Eun Kyung Cho, Suee Lee, Seok Yun Kang, Jae Hong Seo, Sung-Bae Kim, Kyung Hae Jung

Cancer Research and Treatment. 2017;49(2):423-429. Published online 2016 August 3 DOI: https://doi.org/10.4143/crt.2016.191

Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results

Cancer Research and Treatment. 2017;49(2):423-429

Link1 Link2

Link3

Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine

Xavier Pivot, Seock Ah Im, Matthew Guo, Frederik Marmé

Breast Cancer. 2018;25(3):370-374

Link1 Link2

Link3

Clinical characteristics of Korean breast cancer patients in 1998. The Korean Breast Cancer Society

The Korean Breast Cancer Society

Journal of Korean Medical Science. 2000;15(5):569

Link1 Link2 Link3

Clinical Characteristics of Breast Cancer Patients in Korea in Year 2000

Journal of Korean Breast Cancer Society. 2002;5(3):217

Link1 Link2 Link3

Pharmacokinetics of Eribulin Mesilate in Combination With Capecitabine in Patients With Advanced/Metastatic Cancer: Results From a Phase Ib Dose-Escalation Study

C.J. Twelves, M. Nasim, A. Anthoney, N. Cresti, C. Savulsky, C. Johnston, L. Reyderman, J. Wanders, R. Plummer, T.R.J. Evans

Annals of Oncology. 2012;23:ix129

Link1 Link2

Efficacy and Safety of Eribulin in Patients with Triple Negative Metastatic Breast Cancer: Real Life Experience

Ludmila Manzyuk Valentinova

The Breast. 2017;36:S57-S58

Link1 Link2

Mesenchymal Circulating Tumour Cell Analysis to Predict Efficacy of Eribulin for Metastatic Breast Cancer Patients

Yoshiya Horimoto, Emi Tokuda, Fumi Murakami, Katsuya Nakai, Hideo Shimizu, Mitsue Saito

The Breast. 2017;36:S40-S41

Link1 Link2

Efficacy and Safety of Eribulin in Patients with HER2-Negative Metastatic Breast Cancer: Real Life Experience

Larisa Zhilyaeva

The Breast. 2017;36:S53-S54

Link1 Link2

Capecitabine/Bevacizumab Compared to Capecitabine Alone in Pretreated Metastatic Breast Cancer: Results of a Phase III Study)

Kavita Maung, Joyce A. O'Shaughnessy, George W. Sledge

Clinical Breast Cancer. 2003;3(6):375-377

Link1 Link2

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer

Chris Twelves, Ahmad Awada, Javier Cortes, Louise Yelle, Galina Velikova, Martin S. Olivo, James Song, Corina E. Dutcus, Peter A. Kaufman

Breast Cancer: Basic and Clinical Research. 2016;10:BCBCR.S39615

Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.